Kim Jae-kyo, CEO of Hanmi Science (Photo courtesy of Hanmi Science)

[Song Young-doo, Edaily Reporter] Kim Jae-kyo, CEO of Hanmi Science, delivered his first internal message to employees Monday following a sweeping organizational restructuring of Hanmi Group. In the message, Kim emphasized the group’s goal of becoming a global pharmaceutical leader through innovative drug development.

“Hanmi Group stands on the threshold of a new beginning” Kim said in an internal communication. “Over the past 50 years, we have led Korea’s pharmaceutical industry as a symbol of challenge and innovation. Now, we are ready to take on a new challenge developing globally innovative new drugs on the foundation of that proud legacy.”

Kim encouraged employees to embrace a spirit of creativity, challenge and innovation, calling on the company to become a “living pharmaceutical enterprise” that develops first-in-class medicines.

“As a holding company, Hanmi Science, and as the core business unit, Hanmi Pharmaceutical Co. along with more than 30 affiliates, must work in close collaboration to strengthen our identity as a hub of new drug development” he said. “By generating synergies across the group, we will enhance Hanmi’s future value and increase shareholder returns.”

Kim also said the company would continue the legacy of its founder by pursuing global ambitions. “Let’s carry on the founder’s mission of developing better medicines with our own technology, and strive to grow into a global Big Pharma” he said. “Together, let’s write a new chapter in Hanmi Group’s growth story.”

Hanmi Group on Monday also announced a broad organizational overhaul aimed at formulating and executing long-term business strategies. The restructuring focuses on reinforcing coordination between the holding company and its subsidiaries, while establishing a system to drive future growth.

Hanmi Science created two new divisions the Planning and Strategy Division and the Innovation Division. The move is designed to respond swiftly to the rapidly changing global healthcare landscape and to uncover new business opportunities.

The Planning and Strategy Division consists of a Corporate Strategy Team and a Business Strategy Team. The corporate team will develop long-term strategies for the group and its affiliates, while the business team will pursue strategic investments and improve success rates through structured management.

The Innovation Division includes the Connect and Development(C&D) Strategy Team, the Launching and Development(L&D) Strategy Team, and an Intellectual Property Team. These units will play a key role in strengthening the group’s open innovation and licensing strategies, including global commercialization efforts such as licensing out internal technologies and products.